Skip to content

Evaluation of Patients With Surgically Resected High-Risk Melanoma Receiving Adjuvant Therapy in Routine Clinical Practice in the US

This study assessed adjuvant treatment patterns and outcomes in patients with advanced melanoma by BRAF status and relapse location using the Flatiron Health electronic health record-derived deidentified database. The majority of patients with resected stage III melanoma, including patients who experienced relapse, initiated adjuvant treatment with checkpoint inhibitors (CPIs) vs targeted therapies (TTs) in the real-world setting. Early relapse free survival (RFS) and overall survival (OS) outcomes for patients with surgically resected stage III melanoma appear comparable with those reported in randomized clinical studies. Outcomes for patients with distant relapse after adjuvant therapy remain unfavorable and represent a continued unmet medical need.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

Not a healthcare professional? Browse:

Roche's patients website Roche.com

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically